Global α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market, By Type (GluA1, GluA2, GluA3, GluA4), Application (Epilepsy, Seizures, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market Analysis and Size
In recent years, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market is expected to grow on a huge basis during the forecast period due to the increasing incidence of epilepsy. According to the estimates of World Health Organization around 50 million people are suffering from epilepsy. AMPA receptor antagonists are the anticonvulsant agents used to treat partial-onset seizures.
Data Bridge Market Research analyses a growth rate in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market in the forecast period 2023-2030. The expected CAGR of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market is around 5.8% in the mentioned forecast period. The market value is USD 245.4 million in 2022, and it would grow upto USD 385.3 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (GluA1, GluA2, GluA3, GluA4), Application (Epilepsy, Seizures, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (U.S.), GSK plc (U.K.), WOCKHARDT (India), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
|
|
Market Opportunities
|
|
Market Definition
The AMPA receptor (AMPA-R) is a subtype of the ionotropic glutamate receptor that is related with ion channels. They control the flow of calcium and sodium ions into the cell and modulate cell excitability. These receptor antagonists are the anticonvulsants agents that are being used to treat partial-onset seizures in epilepsy patients. They are non-competitive AMPA receptor antagonists, that are involved in excitatory neurotransmission.
Α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market Dynamics
Drivers
- Increased Cases of Epilepsy
The projected proportion of the general population suffering from active epilepsy at a given time is between 4 and 10 per 1000 people. An estimated 5 million people are diagnosed with epilepsy every year worldwide. Epilepsy affects both females and males and all the age groups with worldwide distribution. The incidence and the occurrence of epilepsy are slightly higher in men than women and tend to be observed the most in the elderly, signifying the higher frequency of neurodegenerative diseases, stroke, and tumors in this age-group. This factor is boosting the market growth.
- Growing Usage of AMPA Receptor in Diagnostic Techniques
The use of AMPA receptors in detecting mutated genes boost the market growth. AMPA receptor antibody is found in a subset of patients suffering from autoimmune limbic encephalitis. Reducing antibody levels may be related with therapeutic response; thus, clinical association must be strongly considered. Many indirect fluorescent antibody assay uses AMPA transfected cell lines to detect and semi-quantify AMPA IgG antibody. This factor boosts the market growth.
Opportunities
- Rise in Government Initiatives and Funding
There have been growing investments between diverse organizations that can lead to the growth of the market. For instance, American Epilepsy Society granted fund for extended epilepsy treatment up to US$ 50,000 in March 2021 and are projected to support the establishment of national or global multicenter research initiatives. Every award will provide funding for infrastructure development, organisational planning sessions, or pilot studies, that allows the research programme to compete for future investment.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained and skilled professionals which sometimes fail to use AMPA receptors lead to the failure of detection of epilepsy. Thus, this factor hamper the market growth.
This α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market Scope
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market is segmented on the basis of types, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- GluA1
- GluA2
- GluA3
- GluA4
Application
- Epilepsy
- Seizures
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market Regional Analysis/Insights
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market is analyzed and market size insights and trends are provided by types, application, distribution channel and end-user as referenced above.
The major countries covered in the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market throughout the forecasted period because of the increasing healthcare expenditure and improvements in healthcare infrastructure in this region.
North America dominates the market because of the rising number of cases of epilepsy in this region. Furthermore, rising presence of major market players will further boost the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Market Share Analysis
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market.
Key players operating in the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor market include:
- Merck KGaA (Germany)
- Eisai Co., Ltd. (Japan)
- AstraZeneca (U.K.)
- Sanofi (France)
- Novartis AG (Switzerland)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- WOCKHARDT (India)
- Novo Nordisk A/S (Denmark)
- Glenmark Pharmaceuticals Limited (India)
- Cipla Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Otsuka America Pharmaceutical, Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Corporation (Japan)
- Biocon (India)
SKU-